PHAT logo

PHAT
Phathom Pharmaceuticals Inc

2,356
Mkt Cap
$877.82M
Volume
786,348.00
52W High
$18.31
52W Low
$2.21
PE Ratio
-3.72
PHAT Fundamentals
Price
$11.34
Prev Close
$11.14
Open
$10.91
50D MA
$11.89
Beta
1.24
Avg. Volume
1.14M
EPS (Annual)
-$3.03
P/B
-1.85
Rev/Employee
$471,994.61
$1,668.92
Loading...
Loading...
News
all
press releases
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT
Hennion & Walsh Asset Management Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 114,981 shares of the company's stock, valued at appro...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Analyst Upgrade...
MarketBeat·7d ago
News Placeholder
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays
Barclays raised shares of Phathom Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $16.00 to $18.00 in a report on Friday...
MarketBeat·7d ago
News Placeholder
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Zacks·9d ago
News Placeholder
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
Zacks·10d ago
News Placeholder
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Brokerages
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One...
MarketBeat·14d ago
News Placeholder
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Zacks·16d ago
News Placeholder
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Zacks·17d ago
News Placeholder
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Zacks·17d ago
News Placeholder
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYS shares rise after the FDA accepts NDA for lorundrostat to treat hypertension. A decision from the regulatory body is due on Dec. 22, 2026.
Zacks·23d ago
<
1
2
...
>

Latest PHAT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.